Methods for assessing rna patterns

Abstract

Methods and compositions for the characterizing of cancers by assessing RNA levels, such as determining an RNA pattern, are provided herein. The diagnosis, prognosis, monitoring and treatment or a cancer can be determined by detecting one or more RNAs, such as microRNAs.

1 . A method of characterizing prostate cancer in a human subject comprising: determining the level or presence of PCSA polypeptide in a biological sample from a subject and comparing the level or presence to a reference, wherein a difference in the level or presence as compared to the reference is used to characterize the prostate cancer. 
     
     
         2 . The method of  claim 1 , wherein the characterizing comprises a characterization selected from the group consisting of diagnosis, prognosis, staging, grading, determination of drug efficacy, monitoring the status of the subject's response or resistance to a treatment, selection of a treatment for the prostate cancer, and a combination thereof. 
     
     
         3 . The method of  claim 2 , wherein the subject is non-responsive to a current therapeutic being administered to the subject. 
     
     
         4 . The method of  claim 3 , wherein the therapeutic is a cancer therapeutic. 
     
     
         5 . The method of  claim 1 , wherein the reference is derived from a subject without cancer. 
     
     
         6 . The method of  claim 1 , wherein the reference is derived from the subject over a time course. 
     
     
         7 . The method of  claim 1 , wherein the biological sample comprises a bodily fluid. 
     
     
         8 . The method of  claim 1 , wherein the bodily fluid comprises a bodily fluid selected from the group consisting of peripheral blood, serum, plasma, urine, semen, prostatic fluid, cowper's fluid, pre-ejaculatory fluid, and a combination thereof. 
     
     
         9 . The method of  claim 1 , wherein the bodily fluid comprises plasma or serum. 
     
     
         10 . The method of  claim 1 , further comprising determining the presence or level of one or more protein and/or nucleic acid molecule in the biological sample. 
     
     
         11 . The method of  claim 10 , wherein the one or more protein is selected from EpCAM, CD9, CD63, CD81, PSMA, a BCNP protein biomarker, a metalloproteinase protein biomarker and a combination thereof. 
     
     
         12 . The method of  claim 10 , wherein the one or more nucleic acid molecule is an RNA or DNA molecule. 
     
     
         13 . The method of  claim 1 , wherein one or more membrane vesicles are isolated from the biological sample prior to the determining. 
     
     
         14 . The method of  claim 13 , wherein the one or more membrane vesicles comprise membrane vesicles with a diameter of about 30 nm to about 800 nm. 
     
     
         15 . The method of  claim 13 , wherein the one or more membrane vesicles comprise membrane vesicles with a diameter of about 30 nm to about 200 nm. 
     
     
         16 . The method of  claim 13 , wherein the one or more membrane vesicles are isolated from the biological sample using an isolation technique selected from the group consisting of size exclusion chromatography, density gradient centrifugation, differential centrifugation, nanomembrane ultrafiltration, immunoabsorbent capture, affinity purification, affinity selection, microfluidic separation, and a combination thereof. 
     
     
         17 . The method of  claim 16 , wherein the isolating comprises contacting the biological sample with one or more binding agent that is specific for the PCSA. 
     
     
         18 . The method of  claim 13 , wherein the one or more nucleic acid molecule is a microRNA. 
     
     
         19 . The method of  claim 17 , wherein the one or more binding agent is selected from the group consisting of DNA molecule, RNA molecule, antibody, antibody fragment, aptamer, peptoid, zDNA, peptide nucleic acid (PNA), locked nucleic acids (LNA), lectin, peptide, dendrimer, chemical compound, and a combination thereof. 
     
     
         20 . The method of  claim 17 , wherein the one or more binding agent is elected from the group consisting PSA, PSMA, mAB 5D4, XPSM-A9, XPSM-A10, Galectin-3, E-selectin, Galectin-1, E4 (IgG2a kappa), and a combination thereof. 
     
     
         21 . The method of  claim 13 , wherein the microRNA is selected from the group consisting of mir-1, let-7b, mir-21, mir25, mir-32, mir-93, mir-96, mir-141, mir-143, mir-145, mir-182, mir-183, mir-221, mir-222, mir-301 and mir-375.